Healthcare Industry News: AngioDynamics
News Release - May 20, 2010
AngioDynamics Appoints Lynda Wallace Senior Vice President of Business DevelopmentALBANY, N.Y.--(HSMN NewsFeed)--AngioDynamics (NASDAQ: ANGO ) today announced the appointment of Lynda Wallace, 47, as Senior Vice President of Business Development. In this capacity, Ms. Wallace will lead AngioDynamics’ business development and strategic planning activities and join the Company’s executive leadership team, reporting directly to Jan Keltjens, Chief Executive Officer for AngioDynamics. Her appointment is effective immediately.
During the past 20 years, Ms. Wallace held various positions with Johnson & Johnson, most recently as Worldwide Vice President of the Topical Health Care franchise. Previously, she was Vice President of Business Development for the Johnson & Johnson Medical Devices and Diagnostics sector. Ms. Wallace was also Vice President, US and Worldwide Marketing for Cordis Endovascular; Vice President, Business Development, for Cordis Corporation; and Director of Business Development for Ortho Clinical Diagnostics – all Johnson & Johnson companies.
Ms. Wallace holds a Master of Business Administration from the Wharton School of the University of Pennsylvania, and earned her Bachelor of Arts in Political Philosophy from the University of Delaware.
“Lynda Wallace brings an exceptional depth of knowledge of the medical industry to our company,” commented Mr. Keltjens. “Her extensive category and corporate development experience will be extremely useful as we continue to grow and pursue our strategic objectives. Her addition is an integral step in further strengthening our leadership team and I am delighted to welcome her to AngioDynamics.”
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.